Amyotrophic Lateral Sclerosis Treatment Market

Amyotrophic Lateral Sclerosis Treatment Market Size

The global amyotrophic lateral sclerosis treatment market size was valued at USD 713.3 million in 2023 and is projected to exhibit a 5.5% CAGR from 2024 to 2032. Several factors are boosting the market growth for treating amyotrophic lateral sclerosis (ALS), such as rising incidences of the disease, therapeutic awareness, improvement in therapeutic techniques, and emerging treatment innovations.

Also, the growing ALS cases are notably supporting the market. The National Institutes of Health (NIH) stated that global occurrences of ALS are estimated to increase from 222,801 cases in 2015 to 376,674 cases by the year 2040, which greatly highlights the importance of finding effective therapies and interventions for ALS.

Furthermore, improvement in diagnostics has greatly aided in the early recognition and treatment of ALS. Enhanced healthcare systems' direct identification includes modern neuroimaging techniques, genetic research, and biomarker discovery, thus improving the healthcare systems' capability to recognize ALS in its early stages. This enables timely and appropriate treatment measures that bolster the ALS treatment market.

Amyotrophic lateral sclerosis, or ALS, is a nervous system disorder that affects the nerve cells in the brain and spinal cord, which leads to progressive loss of function. ALS restricts functioning of muscles over the course of time, causing issues with movement, speech, eating, and even breathing. Treating ALS involves developing, producing, and selling various therapeutic products.

Amyotrophic Lateral Sclerosis Treatment Market Trends

• Novel medications have enabled a rapid expansion of the ALS treatment market, which is the primary driving factor. Recent discoveries of genetic and molecular features of ALS have opened new biological avenues to novel drugs. This includes gene therapy, antisense oligonucleotides, and new neuroprotective drugs.
  
• Antisense oligonucleotides are already transforming medicine through gene expression modulation technology and have had accelerated approvals from clinics.
  
• Along with these modern technologies, new neuroprotective drugs that slow down disease progression and protect nerves are in development, greatly expanding the options available for mitigating the ailment.  
  

Amyotrophic Lateral Sclerosis Treatment Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

Based on treatment type, the market is segmented into medication, stem cell therapy, and other treatment types. The medication segment dominated the market with USD 479.7 million in 2023.

• The medication segment of the amyotrophic lateral sclerosis (ALS) treatment market deals with pharmaceutical approaches that aim to control symptoms and modify disease progression. Also, there is prescription drug usage that deals with increasing the survival of patients and minimizing oxidative damage to their neurons, such as riluzole and edaravone.
  
• Edaravone functions by damaging motor neurons, whereas riluzole offers a less aggressive means of increasing life expectancy.
  
• Furthermore, few ALS drug developments focus on more advanced means that address the underlying pathology of ALS.
  
• Therefore, the aforementioned pertaining to progress in research activities along with factors such as increasing awareness and government support fuel market growth in this area.
  

Learn more about the key segments shaping this market

Download Free PDF

Based on disease type, the amyotrophic lateral sclerosis treatment market is divided into sporadic ALS and familial ALS. The sporadic ALS segment accounted for significant market share of 87.3% in 2023.

• The segment with a fragmented approach focuses on the treatment of a specific form of amyotrophic lateral sclerosis (ALS) that is most prevalent, having an average global coverage of about 90-95% of the cases. Unlike familial ALS, sporadic ALS contains very little genetic precursors, making treatment difficult. According to the Centers for Disease Control and Prevention, sporadic ALS is the most widely accepted type of the disorder and covers 90-95% of the cases of ALS.
  
• Moreover, treatments employed currently are aimed at alleviating the symptoms and slowing the progression of the disease with the use of medications such as riluzole and edaravone. Other forms of care include aid in respiration and better nutrition.
  
• Additionally, the constantly evolving pharmaceutical industry is aiming to cope with the unconventional and unsystematic issues which sporadic ALS brings about.
  

Based on route of administration, the amyotrophic lateral sclerosis treatment market is divided into oral and parenteral. The oral segment is expected to reach 725.2 million by the end of 2032.

• Patients have preference towards oral forms of medications, and therefore oral medications for ALS are the most prescribed medications. Medications such as riluzole, which are prescribed to treat the advanced stages of the disease, are suitable in oral form and are preferred by healthcare professionals.
  
• This segment's leadership can be attributed to the ease of adherence towards treatment and reduced costs coupled with the fact that oral medicines are less invasive than parenteral methods, such as IV infusions. As new algorithms for oral medicines continue to emerge, this segment is more likely to keep its leading share in the ALS market.
  

Based on end-use, the amyotrophic lateral sclerosis treatment market is divided into hospitals, rehabilitation centers, specialty clinics, and other end-users. The hospitals segment dominated the market with USD 329.9 million in 2023.

• The hospitals segment is very notable to the ALS treatment market as it delivers integrated care services that include sophisticated diagnostics, multi-specialty treatment, and new technologies. Hospitals provide specialized services such as drug therapy, respiration therapy, and physiotherapy, which are critical for patients with ALS disease.
  
• Moreover, hospitals serve as a center for intensive and exploratory patient care, often utilizing members of the scientific community for clinical research. The segment growth is guided by the improvement of health technology and growing interest and prowess from the medically integrated community in caring for ALS patients.
  

Looking for region specific data?

Download Free PDF

North America amyotrophic lateral sclerosis treatment market is expected to grow at 5.2% CAGR, to reach USD 515.6 million by the end of 2032.

• The U.S. accounts for a major share in North America's amyotrophic lateral sclerosis market because of high disease burden and developed healthcare system.
  
• Also, the U.S. market is associated with the high level of activity in searching for new effective medicines, particularly in the form of a multitude of clinical studies. The availability of Riluzole and Edaravone indicates further treatments can be developed for the country's population.
  
• In addition, having strong pharmaceutical companies in the country along with partnership of academic institutions and biotechnology companies has greatly improved the development of new treatment approaches.
  

The UK amyotrophic lateral sclerosis treatment market is experiencing robust growth in European market.

• The UK is one of the major participants in the ALS treatment industry in Europe, which shows the region's focus towards the management of this debilitating condition. The UK market is serviced through a well-trained healthcare system, particularly the National Health Services (NHS) provides quality healthcare to patients suffering from ALS.
  
• Moreover, the combination of academic institutions, research entities, and pharmaceutical companies has tremendously improved the landscape of the industry, including the new developments of gene therapy and stem cell treatments.
  
• Additionally, non-profit organizations like the Motor Neuron Disease Association (MNDA) assist patients, with their primary focus being advocacy for more funding to be allocated for research work.
  

The Asia Pacific amyotrophic lateral sclerosis treatment market is expected to witness substantial growth of 6% during the analysis period.

• The Asia Pacific region is emerging as a significant market for ALS treatment primarily due to the rising awareness and development in the region's healthcare services.
  
• Moreover, the Asia Pacific region has a lower concentration for the occurrence of ALS, but the number of cases being diagnosed and the focus on neurodegenerative disorders is on the rise. Japan, China, and South Korea are leading this market, with Japan being one of the most advanced in R&D in regenerative medicine and gene therapy.
  
• Additionally, the Asia Pacific region has a unique combination of advanced healthcare systems and poor access to treatment, making it highly fragmented.
  

Amyotrophic Lateral Sclerosis Treatment Market Share

Market competition is stiff for amyotrophic lateral sclerosis (ALS) medication, with pharmaceutical companies greatly investing in innovation and technology. Established pharmaceutical companies are prominent players in the market which significantly invests in research and produces a variety of diagnostic tests and provides further treatments with drugs and new therapeutic techniques. The performance of the main companies improves through mergers, purchases, and joint marketing, which allows these companies to offer more products and enter new markets.

Amyotrophic Lateral Sclerosis Treatment Market Companies

The company profile section includes both companies that have commercial drugs available in the market as well as those that are onto clinical phase development. Prominent players operating in the amyotrophic lateral sclerosis treatment industry include:

• AB Science
• Biogen Inc.
• Biohaven Pharmaceutical (Pfizer, Inc.)
• BrainStorm Therapeutics, Inc.
• Corestemchemon Inc.
• Eledon Pharmaceuticals, Inc.
• F. Hoffmann-La Roche Ltd
• Ionis Pharmaceuticals, Inc.
• ITF Pharma GmbH
• Mitsubishi Tanabe Pharma Corporation
• Otsuka America Pharmaceutical, Inc.
• Sun Pharmaceutical Industries Ltd.
  

Amyotrophic Lateral Sclerosis Treatment Industry News:

• In May 2022, Eledon Pharmaceuticals, Inc. announced encouraging topline results from its Phase IIa clinical trial evaluating Tegoprubart. Tegoprubart is an investigational drug used in the treatment of amyotrophic lateral sclerosis (ALS). The trial result could significantly impact the company’s portfolio and strengthen its market position in the global market.
  

• In June 2024, Mitsubishi Tanabe Pharma America presented the results from Phase 3b MT-1186-A02 post-marketing study of RADICAVA (edaravone) in amyotrophic lateral sclerosis (ALS). The study confirmed the drug's efficacy in slowing disease progression, reinforcing its role as a critical treatment for ALS patients. These findings are expected to enhance RADICAVA's market penetration and solidify Mitsubishi Tanabe's position in the neurodegenerative disease treatment landscape.
  

The amyotrophic lateral sclerosis treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Treatment Type

• Medication
  • Riluzole
  • Edaravone
  • Nuedexta
  • Other medication types
• Stem cell therapy
• Other treatment types

Market, By Disease Type

• Sporadic ALS
• Familial ALS

Market, By Route of Administration

• Oral
• Parenteral

Market, By End-use

• Hospitals
• Rehabilitation centers
• Specialty clinics
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa